Skye launched its Phase 2 trial of nimacimab in obesity in August 2024. This trial, which is the first to also assess a GLP-1/CB1 inhibitor combination, is expected to report interim weight loss data ...

分析师表示，这些结果引发了关于包括monlunabant在内的这一类药物商业可行性的质疑，而且副作用的报告令人担忧，而试验中的减重效果也落后于竞争对手礼来（Eli Lilly & Co.）的药物orforglipron的效果。

财联社9月20日讯（编辑 赵昊）周五（9月20日）美股早盘，丹麦制药巨头诺和诺德股价跌近6%，日内最低报每股126.13美元，为8月9日以来的最低水平。 诺和诺德股价日线图 消息面上，诺和诺德在官网发布了药物“monlunabant”2a期临床试验的主要结果。整体来看，与安慰剂相比，该药物具有显著统计学意义的体重减轻。但在较高剂量的组别中，体重额外减轻的效果有限。 据了解，monlunabant是 ...

The Federal Reserve yesterday cut interest rates by 50 basis points, in its first time cutting rates in four years. And how ...

The device is a variant of Neuralink's brain implant technology, in this case designed to "enable even those who have lost both eyes" to see, according to owner Elon Musk. Separately, progress is ...

Why Corbus Pharmaceuticals sees Novo Nordisk’s controversial approach to obesity drugs as a ticket to a blockbuster.

Data from the US FDA's Adverse Event Reporting System on tirzepatide showed adverse events generally consistent with those ...

The global pandemic of coronavirus disease 2019 (COVID-19) has exacerbated numerous serious social and health problems, including complications of the disease itself, migration, stress, anxiety, and ...

Also Read | From weight loss to detox: Top 5 benefits of Jeera water on an empty stomach For instance, in 2008, a weight-loss drug called rimonabant was taken off the market due to its association ...